Status:
COMPLETED
Study 3: Minocycline Decreases Microglia Activation
Lead Sponsor:
University of Florida
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Hypertension
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
This study is a mechanistic study that will enroll 9 subjects who are participating in NCT02133872 (which is designed to evaluate minocycline to test the hypothesis that minocycline treatment would pr...
Detailed Description
This study (Study 3) will recruit 9 subjects from NCT02133872 (Study1) who will agree to undergo additional autonomic testing and imaging studies at baseline and after 6 months of study treatment. Spe...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Minocycline Subjects:
- Subjects participating in Study 1 will be eligible to participate.
- (For Study 3 Participants only) Willing to travel to Montreal, Canada for specialized imaging of the participant's brain using magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, Autonomic Nervous System Testing and blood drawing- if participant qualifies
- Exclusion Criteria for Minocycline Subjects:
- Female participants with positive pregnancy test.
- Inclusion Criteria for Controls:
- No diagnosis of neurogenic (treatment-resistant) hypertension.
- Not treated with minocycline.
- Willing to travel to Montreal, Canada for brain imaging and testing.
- Able to provide informed consent.
- Exclusion Criteria for Controls:
- Female participants with positive pregnancy test.
Exclusion
Key Trial Info
Start Date :
March 5 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2018
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT02213575
Start Date
March 5 2016
End Date
November 1 2018
Last Update
July 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UF Health Cardiovascular Clinic
Gainesville, Florida, United States, 32610